Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

Fig. 2

a The proportion of disease activity at 24 weeks after the initiation of tofacitinib treatment with or without a concomitant use of MTX. b The proportion of disease activity at 24 weeks after the initiation of baricitinib treatment with or without a concomitant use of MTX. Disease activity was categorized as follows. DAS 28-ESR < 2.6 (remission), 2.6 to < 3.2 (LDA), 3.2–5.1 (MDA), > 5.1 (HDA). MTX methotrexate, LOCF last observation carried forward, ESR erythrocyte sedimentation rate, DAS disease activity score, LDA low disease activity, MDA moderate disease activity, HDA high disease activity

Back to article page